

Press Release

CellFacts Instruments

October 2011

Pfizer Nutrition selects the CellFacts II Instrument for rapid microbiological testing at their Singapore production facility.

CellFacts are pleased to announce the installation of their rapid microbiology testing system at the Pfizer Nutrition site in Singapore. The system has been installed on production lines to monitor the microbiological quality of raw materials during processing. The instrument underwent a rigorous evaluation process before being selected for routine use on the production line.

The system was chosen because of its ability to rapidly detect low levels of bacteria in complex samples. The instrument's unique anti-blocking technology ensures a robust method for the routine analysis of samples with a complex particulate background, without the risk of blockages and instrument down time.

The system has been validated to GMP standards, and the data handling protocols provide a solid audit trail for quality assurance.

Pfizer plan to install the CellFacts II across a number of their international sites over the next few months.

Crawford Dow, CEO of CellFacts commented, "We look forward to working with Pfizer during the implementation stage of this project. The evaluation and validation processes undertaken by the Singapore team have confirmed the technology leadership of the CellFacts II within the rapid microbiology testing sector."

More information on www.cellfacts.com or +44 (0)2746 693436

Contact : Cath Whitaker +44 (0) 7957 363389 – cath.whitaker@cellfacts.com